Carmen P Liskamp1, Geert O Janssens2, Johan Bussink1, Willem J Melchers3, Johannes H Kaanders1, Cornelia G Verhoef1. 1. Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands. 2. Department of Radiation Oncology, Utrecht University Medical Center, Utrecht, The Netherlands. 3. Department of Medical Microbiology, Radboud University Medical Center Nijmegen, The Netherlands.
Abstract
BACKGROUND: The purpose of this retrospective study was to identify prognostic factors in a cohort of patients with oropharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT). METHODS: Medical records of 142 patients treated with (chemo)radiotherapy between September 2005 and September 2011 were reviewed and the human papillomavirus (HPV) status was determined by polymerase chain reaction (PCR) analysis. Potential prognostic factors for 3-year locoregional control and overall survival (OS) were evaluated. RESULTS: HPV-positive patients (n = 82) had locoregional control and OS of 78% and 79%, respectively. Significant prognostic factors on multivariate analysis were smoking (p = .03) for locoregional control and OS, and comorbidity (p = .04) for OS. Further stratification was done according to smoking behavior in HPV-positive patients. Locoregional control in current smokers was 67% compared to 86% in never smokers and former smokers, respectively (p = .02). CONCLUSION: Smoking was the only modifiable prognostic factor in HPV-positive patients. Therefore, active stop-smoking programs must be integrated in the routine management of patients to maximize treatment results.
BACKGROUND: The purpose of this retrospective study was to identify prognostic factors in a cohort of patients with oropharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT). METHODS: Medical records of 142 patients treated with (chemo)radiotherapy between September 2005 and September 2011 were reviewed and the human papillomavirus (HPV) status was determined by polymerase chain reaction (PCR) analysis. Potential prognostic factors for 3-year locoregional control and overall survival (OS) were evaluated. RESULTS:HPV-positive patients (n = 82) had locoregional control and OS of 78% and 79%, respectively. Significant prognostic factors on multivariate analysis were smoking (p = .03) for locoregional control and OS, and comorbidity (p = .04) for OS. Further stratification was done according to smoking behavior in HPV-positive patients. Locoregional control in current smokers was 67% compared to 86% in never smokers and former smokers, respectively (p = .02). CONCLUSION: Smoking was the only modifiable prognostic factor in HPV-positive patients. Therefore, active stop-smoking programs must be integrated in the routine management of patients to maximize treatment results.
Authors: Jonathan J Beitler; Jeffrey M Switchenko; James J Dignam; Mark W McDonald; Nabil F Saba; Dong M Shin; Kelly R Magliocca; Richard J Cassidy; Mark W El-Deiry; Mihir R Patel; Conor E Steuer; Canhua Xiao; Patricia A Hudgins; Ashley H Aiken; Walter J Curran; Quynh-Thu Le Journal: Cancer Date: 2018-12-11 Impact factor: 6.860
Authors: Linda X Yin; Gypsyamber D'Souza; William H Westra; Steven J Wang; Annemieke van Zante; Yuehan Zhang; Eleni M Rettig; William R Ryan; Patrick K Ha; Alicia Wentz; Wayne Koch; David W Eisele; Carole Fakhry Journal: Laryngoscope Date: 2018-03-14 Impact factor: 3.325
Authors: Stephanie Y Chen; Aisling Last; Abhinav Ettyreddy; Dorina Kallogjeri; Benjamin Wahle; Smrithi Chidambaram; Angela Mazul; Wade Thorstad; Ryan S Jackson; Jose P Zevallos; Patrik Pipkorn Journal: Am J Otolaryngol Date: 2021-01-13 Impact factor: 1.808
Authors: Brenen W Papenberg; Jessica L Allen; Steven M Markwell; Erik T Interval; Phillip A Montague; Christopher J Johnson; Scott A Weed Journal: Sci Rep Date: 2020-07-15 Impact factor: 4.379
Authors: Christian Grønhøj; Jakob Schmidt Jensen; Steffen Wagner; Christian Dehlendorff; Jeppe Friborg; Elo Andersen; Claus Wittekindt; Nora Würdemann; Shachi Jenny Sharma; Stefan Gattenlöhner; Jens Peter Klussmann; Christian von Buchwald Journal: Oncotarget Date: 2019-07-23
Authors: Amy Dickinson; Mayank Saraswat; Stina Syrjänen; Tiialotta Tohmola; Robert Silén; Reija Randén-Brady; Timo Carpén; Jaana Hagström; Caj Haglund; Petri Mattila; Antti Mäkitie; Sakari Joenväärä; Suvi Silén Journal: PLoS One Date: 2020-06-15 Impact factor: 3.240